Articles related to DEPRESSION

Groundbreaking research reveals ketamine’s potential as an effective alternative to ECT in treating treatment-resistant depression, offering new hope to millions.

The mental health of cancer patients is an often overlooked aspect of their care. With anxiety and depression being significantly more prevalent in this group, it’s time we pay attention.

The advent of zuranolone may be going beyond postpartum depression, with 87.5% of patients noticing improvements within the first week of treatment for MDD.

Recent findings indicate a significant association between SSRI use in children and delayed puberty, with an odds ratio of 1.44. This underscores the importance of considering potential developmental impacts when prescribing these medications.

A Phase 2B study found that a 25mg dose of psilocybin, combined with psychotherapy, produced a significant drop in patients’ scores on the Montgomery Asberg Depression Rating Scale (MADRS) after 12 weeks. This finding underscores the potential of psilocybin-assisted therapy as a promising treatment for depression.

Despite the potential benefits of ketamine in treating a range of neurological and psychiatric disorders, the FDA has issued warnings about the potential risks associated with its use, emphasizing the need for careful prescription and clinical oversight.